TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau

Several neurodegenerative diseases are driven by the toxic gain-of-function of specific proteins within the brain. Elevated levels of alpha-synuclein (α-Syn) appear to drive neurotoxicity in Parkinson's disease (PD); neuronal accumulation of tau is a hallmark of Alzheimer's disease (AD); and their increased levels cause neurodegeneration in humans and model organisms. Despite the clinical differences between AD and PD, several lines of evidence suggest that α-Syn and tau overlap pathologically. The connections between α-Syn and tau led us to ask whether these proteins might be regulated through a shared pathway. We therefore screened for genes that affect post-translational levels of α-Syn and tau. We found that TRIM28 regulates α-Syn and tau levels and that its reduction rescues toxicity in animal models of tau- and α-Syn-mediated degeneration. TRIM28 stabilizes and promotes the nuclear accumulation and toxicity of both proteins. Intersecting screens across comorbid proteinopathies thus reveal shared mechanisms and therapeutic entry points. DOI: http://dx.doi.org/10.7554/eLife.19809.001

[1]  Maxime W. C. Rousseaux,et al.  Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes , 2015, eLife.

[2]  U. Sengupta,et al.  Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies , 2015, Biological Psychiatry.

[3]  Maxime W. C. Rousseaux,et al.  A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1 , 2015, eLife.

[4]  R. Barker,et al.  The role of tau in the pathological process and clinical expression of Huntington’s disease , 2015, Brain : a journal of neurology.

[5]  E. Masliah,et al.  Parkinson’s Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α-Synuclein , 2015, Neuron.

[6]  E. Masliah,et al.  Parkinson’s Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α-Synuclein , 2015, Neuron.

[7]  Elisabeth L. Moussaud-Lamodière,et al.  Alpha-synuclein and tau: teammates in neurodegeneration? , 2014, Molecular Neurodegeneration.

[8]  A. Gitler,et al.  The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. , 2014, Human molecular genetics.

[9]  D. Ann,et al.  KAPtain in charge of multiple missions: Emerging roles of KAP1. , 2014, World journal of biological chemistry.

[10]  I. Ferrer,et al.  Huntington's disease is a four-repeat tauopathy with tau nuclear rods , 2014, Nature Medicine.

[11]  Bidisha Roy,et al.  Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. , 2014, Human molecular genetics.

[12]  A. Buisson,et al.  Activity-Dependent Tau Protein Translocation to Excitatory Synapse Is Disrupted by Exposure to Amyloid-Beta Oligomers , 2014, The Journal of Neuroscience.

[13]  J. Clarimón,et al.  Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies. , 2013, Journal of neuropathology and experimental neurology.

[14]  A. Saykin,et al.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders. , 2013, American journal of neurodegenerative disease.

[15]  Bin Zhang,et al.  Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.

[16]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[17]  Hyojin Kang,et al.  RAS–MAPK–MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1 , 2013, Nature.

[18]  Thomas C. Südhof,et al.  Systematic Mutagenesis of α-Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities , 2012, The Journal of Neuroscience.

[19]  David S. Park,et al.  Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease , 2012, Proceedings of the National Academy of Sciences.

[20]  J. Lancia,et al.  Tau oligomers and tau toxicity in neurodegenerative disease. , 2012, Biochemical Society transactions.

[21]  D. Dinsdale,et al.  Sustained translational repression by eIF2α-P mediates prion neurodegeneration , 2012, Nature.

[22]  M. Chesselet,et al.  A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice , 2012, Neurotherapeutics.

[23]  Jason I. Herschkowitz,et al.  The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo , 2011, Proceedings of the National Academy of Sciences.

[24]  L. Buée,et al.  Nuclear Tau, a Key Player in Neuronal DNA Protection* , 2010, The Journal of Biological Chemistry.

[25]  Dan Liu,et al.  Genome-wide YFP Fluorescence Complementation Screen Identifies New Regulators for Telomere Signaling in Human Cells* , 2010, Molecular & Cellular Proteomics.

[26]  R. Kayed,et al.  Preparation and characterization of neurotoxic tau oligomers. , 2010, Biochemistry.

[27]  T. Südhof,et al.  α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in Vitro , 2010, Science.

[28]  Maojun Yang,et al.  MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. , 2010, Molecular cell.

[29]  E. Yaksi,et al.  Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.

[30]  J. Trojanowski,et al.  Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline , 2010, The Journal of Neuroscience.

[31]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[32]  Aideen Long,et al.  Statistical methods for analysis of high-throughput RNA interference screens , 2009, Nature Methods.

[33]  Yang Shi,et al.  SCFβ-TRCP controls oncogenic transformation and neural differentiation through REST degradation , 2008, Nature.

[34]  M. Cookson,et al.  Cell systems and the toxic mechanism(s) of α-synuclein , 2008, Experimental Neurology.

[35]  David S. Park,et al.  The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage , 2007, Proceedings of the National Academy of Sciences.

[36]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[37]  J. Parvin,et al.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. , 2006, Human molecular genetics.

[38]  A. Lang,et al.  Interface between tauopathies and synucleinopathies: A tale of two proteins , 2006, Annals of neurology.

[39]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[40]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[41]  D. Price,et al.  Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation , 2004, The Journal of Neuroscience.

[42]  Christina A. Wilson,et al.  Degradative organelles containing mislocalized α- and β-synuclein proliferate in presenilin-1 null neurons , 2004, The Journal of cell biology.

[43]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[44]  D. Dickson,et al.  Colocalization of Tau and Alpha‐Synuclein Epitopes in Lewy Bodies , 2003, Journal of neuropathology and experimental neurology.

[45]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[47]  D. Geschwind,et al.  Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila , 2002, Neuron.

[48]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  K. Kosaka,et al.  Relationship in the formation process between neurofibrillary tangles and Lewy bodies in the hippocampus of dementia with Lewy bodies brains , 2002, Journal of the Neurological Sciences.

[50]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[51]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[52]  P. Chambon,et al.  Bonus, a Drosophila homolog of TIF1 proteins, interacts with nuclear receptors and can inhibit betaFTZ-F1-dependent transcription. , 2001, Molecular cell.

[53]  P. Chambon,et al.  Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development. , 2000, Development.

[54]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[55]  Kazuko Aoto,et al.  Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies , 1999, Brain Research.

[56]  M. Cookson,et al.  Cell systems and the toxic mechanism(s) of alpha-synuclein. , 2008, Experimental neurology.

[57]  A Dürr,et al.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.

[58]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[59]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[60]  K. Rajewsky,et al.  A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. , 1995, Nucleic acids research.